CLAIM #18595 · CVS Health Corp (CVS) · 2025Q3 earnings call · Oct 29, 2025 · due Dec 31, 2026
“In our Health Services segment, we expect improvement in our Health Care Delivery business, primarily driven by Oak Street Health.”
Brian O. Newman · CFO
How to check this claim
Look at: Health Care Delivery business operating performance (segment-level results or commentary), driven by Oak Street Health, within Health Services segment
It came true if: Health Care Delivery operating loss narrower or operating income higher year-over-year in FY2026 vs FY2025, as described in company reporting/commentary
Where: CVS Health 10-K/Q4 2026 earnings release and segment commentary, and Investor Day (December 2025) guidance details
In context
“of the key headwinds and tailwinds for 2026. Consistent with past practice, we expect to provide formal 2026 guidance at our Investor Day in December. Beginning with our Health Care Benefits business, we expect another year of meaningful margin improvement at Aetna. This includes another year of progress in our Medicare Advantage business, supported by our disciplined approach to plan design and footprint in individual as well as repricing opportunities in our group business. We also expect a tailwind from our exit of the individual exchange business. Although our conversations with our Medicaid state partners continue to progress and this business has performed in line with our expectations this year, we are taking a cautious outlook in light of the broader pressures across the industry. In our Health Services segment, we expect improvement in our Health Care Delivery business, primarily driven by Oak Street Health. In our Caremark business, we expect modestly lower growth as we continue our work to transition our contracts towards drug level pricing over the next few years. Altogether, we expect the segment to deliver low single-digit adjusted operating income growth next year. And in our Pharmacy & Consumer Wellness segment, we are encouraged by our strong performance this year and expect this momentum to continue into next year. While challenges, including reimbursement pressure and the impact of shifting consumer dynamics remain in this business, we currently expect the trajectory to improve relative to our long-term expectation of a 5% decline. I would also remind everyone that consistent with past practice, the impact of prior year reserve development and other out-of-period items should be rem”
Verify independently
SEC filings for CVS ↗ · Claim quote is verbatim from the 2025Q3 earnings call.